3 Phosphoinositide Dependent Protein Kinase 1 Market Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2027

The global 3 phosphoinositide dependent protein kinase 1 market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). PDK1 or 3-Phosphoinositide-dependent kinase 1 is a key member of the AGC protein kinase family and is important in a variety of cellular functions which leads to the activation of the PI3K signalling pathway which is an event that is associated with the onset and progression of several human cancers. The major factor contributing to the growth of the market is the increasing prevalence of breast cancer across the globe.

According to the World Health Organization (WHO), breast cancer is the globe's most prevalent cancer. Additionally, there were 2.3 million women diagnosed with breast cancer with a mortality rate of 685,000 globally in 2020. Furthermore, as of December 2020, there were 7.8 million women alive while being diagnosed with breast cancer in the past 5 years. Hence, the increasing prevalence of this disease is driving the growth of the global 3 phosphoinositide dependent protein kinase 1 market.

To Request a Sample of our Report on 3 Phosphoinositide Dependent Protein Kinase 1 Market: https://www.omrglobal.com/request-sample/3-phosphoinositide-dependent-protein-kinase-1-market

Some major players operating in the market include Boehringer Ingelheim GmbH, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in May 2019, Novartis announced the approval of Piqray (alpelisib) tablets from the US FDA. It is used in combination with the endocrine therapy fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Boehringer Ingelheim GmbH, AstraZeneca plc, and Bayer AG, among others.

(Get 15% Discount on Buying this Report)

A full Report of 3 Phosphoinositide Dependent Protein Kinase 1 Market is Available @ https://www.omrglobal.com/industry-reports/3-phosphoinositide-dependent-protein-kinase-1-market

Global 3 Phosphoinositide Dependent Protein Kinase 1 Market Report by Segment

By Type

• HCI-1708

• AR-12

• PHT-427

• SNS-229

• Others

By Application

• Clinic

• Hospital

• Others

Global 3 Phosphoinositide Dependent Protein Kinase 1 Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.